Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin E Gore

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Journal of the National Cancer Institute|April 30, 2011
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinibBrian I Rini, Darrel P Cohen, Dongrui R Lu, et al.
Clinical Genitourinary Cancer|July 17, 2017
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical TrialsNizar M Tannir, Robert A Figlin, Martin E Gore, et al.
Cancer|September 24, 2010
Sunitinib in metastatic renal cell carcinoma patients with brain metastasesMartin E Gore, Subramanian Hariharan, Camillo Porta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2010
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC seriesRoshan Agarwal, Charlie Gourley, Timothy J Perren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2003
Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy?Desiree F Kolomainen, Roger A'Hern, Fareeda Y Coxon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2012
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II studyPeter Mulders, Robert Hawkins, Paul Nathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatmentViviane Hess, Roger A'Hern, Nazar Nasiri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapyMohan Hingorani, Christine L White, Shane Zaidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinomaChooi P Lee, Poulam M Patel, Peter J Selby, et al.
The Lancet. Oncology|April 20, 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trialRobert J Motzer, Bernard Escudier, Piotr Tomczak, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|April 30, 2011
Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinibBrian I Rini, Darrel P Cohen, Dongrui R Lu, et al.
Clinical Genitourinary Cancer|July 17, 2017
Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical TrialsNizar M Tannir, Robert A Figlin, Martin E Gore, et al.
Cancer|September 24, 2010
Sunitinib in metastatic renal cell carcinoma patients with brain metastasesMartin E Gore, Subramanian Hariharan, Camillo Porta, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2010
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC seriesRoshan Agarwal, Charlie Gourley, Timothy J Perren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2003
Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy?Desiree F Kolomainen, Roger A'Hern, Fareeda Y Coxon, et al.
European Journal of Cancer (Oxford, England : 1990)|January 31, 2012
Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II studyPeter Mulders, Robert Hawkins, Paul Nathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatmentViviane Hess, Roger A'Hern, Nazar Nasiri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2008
Radiation-mediated up-regulation of gene expression from replication-defective adenoviral vectors: implications for sodium iodide symporter gene therapyMohan Hingorani, Christine L White, Shane Zaidi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2006
Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinomaChooi P Lee, Poulam M Patel, Peter J Selby, et al.
The Lancet. Oncology|April 20, 2013
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trialRobert J Motzer, Bernard Escudier, Piotr Tomczak, et al.
Pageof 6